Trials / Completed
CompletedNCT02868099
Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
A Multi-center, Randomized, Placebo-controlled, Double-blinded Then Open 2 Stages Clinical Trial to Evaluate the Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 203 (actual)
- Sponsor
- Kyowa Kirin China Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to evaluate the efficacy and safety of romiplostim for injection in adlut subjects with persistent or chronic primary immune thrombocytopenia (ITP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Romiplostim | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2017-02-01
- Completion
- 2017-06-01
- First posted
- 2016-08-16
- Last updated
- 2024-04-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02868099. Inclusion in this directory is not an endorsement.